CXCL16

Across TCGA pan-cancer cohorts, CXCL16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CXCL16 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CXCL16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CXCL16 expression acts as an unfavorable survival marker.

HNSC, BLCA, and SKCM are the cancer types where CXCL16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.710	.001	24	view →
BLCA	OS	Median	III,IV	0.133	0.684	<.001	18	view →
SKCM	DFS	Median	All	0.058	0.757	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CXCL16–HNSC (DFS)

Open the HNSC breakdown →